drugset

drugset / Trial / NCT04525729

Rituximab and RASi in Patients with IgAN

NCT04525729 ↗

Phase 4 Completed 116 enrolled Nan Chen,MD Dongfang Hospital Affiliated to Tongji University · collab Ningbo Municipal Yinzhou District No.2 Hospital · collab Ruijin Hospital · collab Shanghai Pudong New Area People's Hospital · collab Sir Run Run Shaw Hospital · collab Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collab Third Affiliated Hospital, Sun Yat-Sen University · collab Tongji Hospital · collab Xiamen Hong'ai Hospital · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.

Timeline

Start: 2020-07-01
Primary completion: 2024-03-30
Completion: 2024-03-30

Publications

Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	1 g	Intravenous

Indications